APA Alıntı

Birkeland, E., Busch, C., Berge, E. O., Geisler, J., Jönsson, G., Lillehaug, J. R., . . . Lønning, P. E. (2013). Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Springer Netherlands.

Chicago Stili Alıntı

Birkeland, Einar, Christian Busch, Elisabet Ognedal Berge, Jürgen Geisler, Göran Jönsson, Johan Richard Lillehaug, Stian Knappskog, ve Per Eystein Lønning. Low BRAF and NRAS Expression Levels Are Associated With Clinical Benefit From DTIC Therapy and Prognosis in Metastatic Melanoma. Springer Netherlands, 2013.

MLA Alıntı

Birkeland, Einar, et al. Low BRAF and NRAS Expression Levels Are Associated With Clinical Benefit From DTIC Therapy and Prognosis in Metastatic Melanoma. Springer Netherlands, 2013.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..